SYRS News and Press, Syros Pharmaceuticals Inc. From 09/17/21

Gainers: Corvus Pharmaceuticals (NASDAQ:CRVS) +73%, Innate Pharma IPHA +51%, SmileDirectClub (NASDAQ:SDC) +12%, Biomerica (NASDAQ:BMRA) +9%, I-Mab (NASDAQ:IMAB) +6%. Losers: Protagonist Therapeutics PTGX -62%, TCR2 Therapeutics TCRR -31%,...

Management to Host Conference Call on Monday, September 20, 2021 at 4:00 p.m. ET Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new data from the dose-escalation portion...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Deborah Dunsire, M.D., to the Company’s Board of Directors. Dr. Dunsire is a highly respected industry veteran with more than 30 ...

Initial Data from the Phase 2 Trial Expected in 2022 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dosed in the SELECT-AML-1 clinical trial of tamibarotene, ...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at two upcoming investor conferences in September. Management wil...

Syros Pharmaceuticals, Inc. (SYRS) Q2 2021 Earnings Conference Call August 5, 2021 08:30 ET Company Participants Naomi Aoki - Vice President of Investor Relations & Corporate Communications Nancy Simonian - Chief Executive Officer David Roth - Chief Medical Officer Gerald Quirk - Chief Op...

The following slide deck was published by Syros Pharmaceuticals, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Syros Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation

Score Media and Gaming (NASDAQ:SCR) +65% Penn National Gaming inks deal to acquire Score Media and Gaming Ensysce Biosciences (NASDAQ:ENSC) +38% announces notice of allowance from the U.S. Patent and trademark office for Patent entitled “compositions comprising enzyme-cl...

Today Announced Agreement with Roche to Evaluate SY-5609 in Combination with Immunotherapy in BRAF-Mutant Colorectal Cancer Patients Additional Dose Escalation Data for SY-5609 to be Highlighted in Oral Presentation at ESMO Congress; On Track to Advance into Phase 1 Expansion ...

Clinical Trial Cohort to Evaluate SY-5609 in Combination with Atezolizumab, a PD-L1 Checkpoint Inhibitor Marks First Clinical Investigation of Selective CDK7 Inhibitor with Immunotherapy Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines th...